Answers are grounded in this paper and cite their sources.
Early warning regarding the risk of cerebral or myocardial ischemia and death when using hexamethonium and apresoline in patients with coronary or cerebral artery obstruction.
A report to the Council on Pharmacy and Chemistry¹in 1949 described actions of adrenolytic or sympatholytic and ganglionic blocking drugs then available. It warned that these drugs should be used with caution if at all in patients who have partial obstruction of coronary or cerebral arteries. Such obstruction often exists along with the systemic arterial changes of hypertension or peripheral vascular disease. In patients of this type cerebral or myocardial ischemia has developed with reduction of blood pressure following administration of drugs, and occasionally death has occurred. Since that report¹several other drugs capable of blocking the efferent pathways of the sympathetic nervous system have been developed. One, hexamethonium chloride ("methium"), is an orally effective ganglionic blocking agent. Another, 1-hydrazinophthalazine hydrochloride (C-5968, "apresoline"), is a weakly adrenolytic and sympatholytic agent having several complex actions. These two drugs have been released by the Federal Food and Drug Administration
No takes yet. Share an insight, caveat, or question.
K. S. Grimson (1952) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: